File Download
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1155/2015/502089
- Scopus: eid_2-s2.0-84929648987
- WOS: WOS:000363703200001
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Comparison of Enoxaparin and Warfarin for Secondary Prevention of Cancer-Associated Stroke
Title | Comparison of Enoxaparin and Warfarin for Secondary Prevention of Cancer-Associated Stroke |
---|---|
Authors | |
Issue Date | 2015 |
Citation | Journal of Oncology, 2015, v. 2015 How to Cite? |
Abstract | Copyright © 2015 Hyemin Jang et al.Background. The aim of this study was to determine which anticoagulant is superior for secondary prevention of cancer-associated stroke, using changes in D-dimer levels as a biomarker for recurrent thromboembolic events. Methods. We conducted a retrospective, single center observational study including patients with cancer-associated stroke who were treated with either enoxaparin or warfarin. Blood samples for measuring the initial and follow-up D-dimer levels were collected at admission and a median of 8 days after admission, respectively. Multiple logistic regression analysis was conducted to evaluate the factors that influenced D-dimer levels after treatment. Results. Although the initial D-dimer levels did not differ between the two groups, the follow-up levels were dramatically decreased in patients treated with enoxaparin, while they did not change with use of warfarin (3.88 μg/mL versus 17.42 μg/mL, p = 0.026). On multiple logistic regression analysis, use of warfarin (OR 12.95; p = 0.001) and the presence of systemic metastasis (OR 18.73; p = 0.017) were independently associated with elevated D-dimer levels (≥10 μg/mL) after treatment. Conclusion. In cancer-associated stroke patients, treatment with enoxaparin may be more effective than treatment with warfarin for lowering the D-dimer levels. Future prospective studies are warranted to show that enoxaparin is better than warfarin for secondary prevention in cancer-associated stroke. |
Persistent Identifier | http://hdl.handle.net/10722/238134 |
ISSN | 2021 Impact Factor: 4.501 |
ISI Accession Number ID |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Jang, Hyemin | - |
dc.contributor.author | Lee, Jung Jae | - |
dc.contributor.author | Lee, Mi Ji | - |
dc.contributor.author | Ryoo, Sookyung | - |
dc.contributor.author | Yoon, Chang Hyo | - |
dc.contributor.author | Kim, Gyeong Moon | - |
dc.contributor.author | Chung, Chin Sang | - |
dc.contributor.author | Lee, Kwang Ho | - |
dc.contributor.author | Bang, Oh Young | - |
dc.contributor.author | Kim, Suk Jae | - |
dc.date.accessioned | 2017-02-03T02:13:09Z | - |
dc.date.available | 2017-02-03T02:13:09Z | - |
dc.date.issued | 2015 | - |
dc.identifier.citation | Journal of Oncology, 2015, v. 2015 | - |
dc.identifier.issn | 1687-8450 | - |
dc.identifier.uri | http://hdl.handle.net/10722/238134 | - |
dc.description.abstract | Copyright © 2015 Hyemin Jang et al.Background. The aim of this study was to determine which anticoagulant is superior for secondary prevention of cancer-associated stroke, using changes in D-dimer levels as a biomarker for recurrent thromboembolic events. Methods. We conducted a retrospective, single center observational study including patients with cancer-associated stroke who were treated with either enoxaparin or warfarin. Blood samples for measuring the initial and follow-up D-dimer levels were collected at admission and a median of 8 days after admission, respectively. Multiple logistic regression analysis was conducted to evaluate the factors that influenced D-dimer levels after treatment. Results. Although the initial D-dimer levels did not differ between the two groups, the follow-up levels were dramatically decreased in patients treated with enoxaparin, while they did not change with use of warfarin (3.88 μg/mL versus 17.42 μg/mL, p = 0.026). On multiple logistic regression analysis, use of warfarin (OR 12.95; p = 0.001) and the presence of systemic metastasis (OR 18.73; p = 0.017) were independently associated with elevated D-dimer levels (≥10 μg/mL) after treatment. Conclusion. In cancer-associated stroke patients, treatment with enoxaparin may be more effective than treatment with warfarin for lowering the D-dimer levels. Future prospective studies are warranted to show that enoxaparin is better than warfarin for secondary prevention in cancer-associated stroke. | - |
dc.language | eng | - |
dc.relation.ispartof | Journal of Oncology | - |
dc.rights | This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. | - |
dc.title | Comparison of Enoxaparin and Warfarin for Secondary Prevention of Cancer-Associated Stroke | - |
dc.type | Article | - |
dc.description.nature | published_or_final_version | - |
dc.identifier.doi | 10.1155/2015/502089 | - |
dc.identifier.scopus | eid_2-s2.0-84929648987 | - |
dc.identifier.volume | 2015 | - |
dc.identifier.spage | null | - |
dc.identifier.epage | null | - |
dc.identifier.eissn | 1687-8469 | - |
dc.identifier.isi | WOS:000363703200001 | - |
dc.identifier.issnl | 1687-8450 | - |